Dr. Vishal Navani
Positions
Assistant Professor - Medicine
Cumming School of Medicine, Department of Oncology
Medical Oncologist
Arthur J.E. Child Comprehensive Cancer Centre
Member
Arnie Charbonneau Cancer Institute
Contact information
Phone number
Office: 403.521.3688
Location
Tom Baker Cancer Centre: Physicians Offices CC107
Preferred method of communication
Administrative Assistant
Adrianna Braun
Email: adrianna.braun@ahs.ca
Office: 403.521.3866
Background
Educational Background
Master of Arts Medical Sciences, University of Oxford,
Bachelor of Medicine Bachelor of Surgery Imperial College London,
Member of the Royal Colleges of Physicians UK Internal Medicine,
Fellow of the Royal Australasian College of Physicians Medical Oncology,
Biography
Dr. Navani is a staff medical oncologist at the Tom Baker Cancer Centre and assistant professor of medicine at the University of Calgary. He previously graduated from Oxford and Imperial College London. He holds both Membership of the Royal College of Physicians of the United Kingdom and Fellowship of the Royal Australasian College of Physicians.
He is the lead for Glans Look, Canada’s largest lung cancer database and his award winning research has been published extensively in high impact journals, including JAMA Oncology, The Lancet Oncology and European Urology. He has gained several hundred thousand dollars in competitive grant funding and has mentored several post-graduate medicine trainees to international oncology ASCO merit awards. He has been an invited speaker for several national conferences including recently moderating the Canadian Kidney Cancer Forum and chairing Oncology Education's "Best of Precision Oncology".
He has contributed as a clinical expert to CADTH national drug reimbursement decisions and provides clinical development advice to a number of life science companies, alongside being a member of the Canadian Real World Cancer Evaluation platform clinical advisory group. He serves as the departmental thoracic oncology research group lead in Calgary and sits on the Cancer Control Alberta IIT award review panel.
Research
Areas of Research
Real World Evidence and its role in informing therapeutic decision making
My academic focus includes the interrogation of large real world datasets spanning tumour streams in order to generate practical insights that can be used in the clinic. I am director at Glans Look, one of North America’s largest lung cancer databases and oversee a broad programe of research here that includes fellows, research coordinators nd programme managers with dozens of published manuscripts and competitive funding received.
My work on the International Metastatic Renal Cell Carcinoma Database (IMDC), collaborating with founder and division lead Prof. Daniel Heng, has been extensively published in high impact journals such as JAMA Oncology and won multiple academic awards, including an ASCO Merit Award. I have helped to curate and develop the database on an ongoing basis including expanding the translational biomarker based components of our research, with funded Marathon of Hope grants supporting this.
Novel Immunotherapy Approaches to treat Solid Tumours
Active clinical trialist across all phases of clinical development, attempting to identify and validate novel therapeutic targets. We work with co-operative group and industry partners to recruit patients on potentially practice-changing studies in areas of high unmet need, with a focus on lung and genitourinary malignancies. Some highlights of this research include:
- Invited commentaries in the Lancet Oncology & Journal of Clinical Oncology
- Opening the first novel immunotherapeutic study examining TIGIT as a target in Calgary
- Providing clinical development advice to >30 sponsors & CROs to improve protocol design, recruitment and statistical plans
Publications
In the News
- Lung Metastases, Cytoreductive Nephrectomy Use Associated With Responses to First-Line Immune-Oncology Combinations in mRCC.
- Several Studies Evaluate Agents in the First-Line, Second-Line, and Later Treatment of Advanced Kidney Cancer.
- ASCO GU 2022: Predictors of Objective Response to First-Line Immuno-Oncology Combination Therapies in Metastatic Renal Cell Carcinoma: Results from the IMDC.
- Clinically Meaningful Activity with Second Line Cabozantinib.
Are you the profile owner?
Login to edit.